NCT02442297: T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) for Patients With HER2-Positive CNS Tumors

NCT02442297
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 3 Years and older (Child, Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02442297

Comments are closed.

Up ↑